Another finding in the study by Elez et al17 is the suggestion of a cross-talk between the MAPK pathway and the WNT pathway that may play a role regarding the antitumor activity of BRAF-targeted therapy in patients with CRC. This evidence concerns the gene BRAF and colorectal carcinoma.